The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

Trial overview




Durvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial.

Eligibility criteria

  • Untreated stage IV Mesothelioma, please enquire for more details.

Study details

The treatment is comparing standard of care chemotherapy to chemotherapy with Atezolizumab, the study is randomised with a ratio of 2:1. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.